10X Genomics, Inc.

10X Genomics, Inc., headquartered in Pleasanton, California, manufactures single-cell and spatial transcriptomics platforms, reagent kits, consumables, and diagnostic instruments sold to federal research agencies as a prime contractor in full-and-open competition with no set-aside posture. The company is a for-profit corporation registered as a manufacturer of goods operating under NAICS 334516 (Analytical Laboratory Instrument Manufacturing), 325414 (Biological Product Manufacturing), and 325413 (In-Vitro Diagnostic Substance Manufacturing), with primary PSC coding in Laboratory Equipment and Supplies and In Vitro Diagnostic Substances.

10X Genomics' federal footprint is heavily concentrated in the National Institutes of Health system. The top five customer agencies—all NIH components—account for 57% of recent award volume. The National Institute on Aging leads by potential dollar value (169 awards, $20.1 million), while the National Institute of Allergy and Infectious Diseases leads by award count (319 awards, $14.5 million). The company also serves the National Heart Lung and Blood Institute (74 awards, $3.1 million), the National Institute on Drug Abuse (30 awards, $3.4 million), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (95 awards, $2.9 million). Department of Veterans Affairs Veterans Integrated Service Networks place recurring purchase orders and indefinite delivery contracts for genomic analysis reagents and consumables. The concentration is acute: five agencies account for 61% of combined potential value.

Work delivered through 10X Genomics includes Chromium and Chromium X single-cell partitioning systems, GEM-X gene expression and multiome kits, Visium and Xenium spatial transcriptomics platforms, single-cell RNA sequencing reagent bundles, dual index kits, chip kits, and annual maintenance and assurance plans for laboratory instruments. Representative examples include a $7 million single-award indefinite delivery contract with the National Institute on Aging (through July 2029) for optimization slides, reagent kits, and delivery methods supporting neurological disease research; a $249,963.94 purchase order from NIAID for NGS project reagents (September 2025); a $559,550 sole-source purchase order from NIAMS for a 10X Genomics Atera Platform integrated spatial biology system (August 2026); and a $698,916.06 sole-source purchase order from Veterans Integrated Service Network 2 for gene expression reagents (September 2025).

10X Genomics holds two named indefinite delivery contracts: a $7 million single-award IDIQ with the National Institute on Aging (effective July 2024 through July 2029) and a $220,000 single-award IDIQ with Veterans Integrated Service Network 21 (September 2026 through August 2028). The company also places work under the NIH-wide Blanket Purchase Agreement (75N98022A00032), which has generated 199 task orders worth $4.1 million in combined potential value, and under the NIH IDC 75N95024D00029 (66 task orders, $7.5 million combined potential value). These vehicles reflect 10X Genomics' role as a direct supplier to federal research infrastructure rather than a subcontractor or systems integrator.

Recent activity has remained steady with 40 awards in 2026 (year-to-date as of mid-October), 137 in 2025, and 165 in 2024, following higher volumes of 205 awards in 2022 and 181 in 2023. Combined potential value across all awards totals $71.7 million with $62.2 million obligated (87% realization). The recompete cliff in the next twenty-four months shows 38 awards with ultimate completion dates totaling $3.6 million in combined potential value—modest relative exposure.

10X Genomics operates as a prime contractor on 100% of tracked federal awards (1,325 primes versus 6 sub-awards). The two sub-awards identified are to The Johns Hopkins University Applied Physics Laboratory LLC for directed energy health research materials and supplies (December 2024 and August 2025), representing minimal subcontract footprint. The company competes full-and-open without small-business set-aside designation across its federal portfolio, though one NIAID purchase order for Visium HD spatial gene expression kits (September 2024, $11,049) was marked Total Small Business set-aside, indicating periodic exposure to that category.

The portfolio demonstrates sustained federal dependency on 10X Genomics' proprietary single-cell and spatial transcriptomics technology across the NIH research ecosystem, with award velocity and dollar concentration reflecting the vendor's established position as a critical supplier of molecular analysis infrastructure to federal biomedical research institutions. No competing subcontract or prime relationships with other vendors emerge in the source material.